inhibitors among individuals with type 1 diabetes (T1D), according to a research letter published online October 23 in the Journal of the American Medical Association. Piaopiao Li, from the Emory ...

MONDAY, Oct. 28, 2024 (HealthDay News) — From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) ...

MONDAY, Oct. 28, 2024 (HealthDay News) -- From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) ...

Proton pump inhibitors (PPIs) are a group of drugs whose purpose it is to reduce stomach acid. They have been used to treat a wide of gastric acid-related illnesses for more than 30 years and are ...

Tyra Biosciences (NASDAQ:TYRA) is gearing up to report data from its phase 1/2 study, using its FGFR3-inhibitor TYRA-300 ... service on Seeking Alpha Marketplace. If you like what you read here ...

A new generation has emerged: Generation Alpha. While the official age range for these youngsters is still heavily up for debate (some maintain the generation began in 2012 and runs through 2024 ...

In fact, sotagliflozin is marked as an "other SGLT2 inhibitor," with uncertainty regarding its impact on HFrEF in patients without diabetes. This is an important notation, as many heart failure ...

Type 2 diabetes occurs when the body does not make enough insulin or use it correctly. Some people require insulin or other medication, while others can manage blood sugar levels through diet and ...

Similar to the findings of CAPPP and ASCOT-BPLA, the ALLHAT demonstrated an ACE inhibitor’s superiority over thiazides in reducing the rate of new-onset diabetes. However, the trial did note ...